US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ホーム
投資
株式
アメリカ
USOTC
Genesis Growth Tech Acquisition Corporation (EM) (GGAAF) 銘柄情報

Genesis Growth Tech Acquisition Corporation (EM) (GGAAF)

5.38

0.00

(0.00%)

終了 7月11日 5:00AM

Genesis Growth Tech Acquisition Corporation (EM) (GGAAF) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

5.38

( - )

買値

0.00

売値

0.00

出来高

-

平均取引量 (3 か月)

US$ 0

財務取引量

-

0.00 日の範囲 0.00

5.38 52 週間の範囲 5.38

時価総額

企業価値

36.846M

前日終値

5.38

始値

-

時刻

最終取引時間

VWAP

-

歳入

-

純利益

-1.2M

発行済株式数

6,338,637

浮動株比率 (%)

0.22%

機関投資家保有比率 (%)

-

配当利回り

PER

-28.87

株価売上高倍率 (PSR)

-

1 株当たり利益 (EPS)

-0.19

ベータ

-12.86

NeuroMind AI Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus its efforts on identifying technology co... NeuroMind AI Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus its efforts on identifying technology companies operating primarily within the consumer internet industry in Europe, Israel, the United Arab Emirates, or the United States. The company was formerly known as Genesis Growth Tech Acquisition Corp. and changed its name to NeuroMind AI Corp. in May 2024. NeuroMind AI Corp. was incorporated in 2021 and is based in Hergiswil, Switzerland. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.genesisgrowthtechspac.com

本社

Hergiswil, Switzerland

設立

2026

Genesis Growth Tech Acquisition Corporation (EM) is listed in the sector of the その他OTC with ticker GGAAF. The last closing price for Genesis Growth Tech Acqu... (EM) was US$5.38. Over the last year, Genesis Growth Tech Acqu... (EM) shares have traded in a share price range of US$ 5.38 to US$ 5.38.

Genesis Growth Tech Acqu... (EM) currently has 6,338,637 shares in issue. The market capitalisation of Genesis Growth Tech Acqu... (EM) is US$34.10 million. Genesis Growth Tech Acqu... (EM) has a price to earnings ratio (PE ratio) of -28.87.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	5.38	5.38	5.38	0	0	CS
26	0	0	5.38	5.38	5.38	0	0	CS
52	0	0	5.38	5.38	5.38	1	5.38	CS
156	-5.12	-48.7619047619	10.5	18.97	0.015	2221	11.22963839	CS
260	-5.12	-48.7619047619	10.5	18.97	0.015	2221	11.22963839	CS

GGAAF - Frequently Asked Questions (FAQ)

What is the current Genesis Growth Tech Acquisition Corporation (EM) share price?

The current share price of Genesis Growth Tech Acquisition Corporation (EM) is US$ 5.38

How many Genesis Growth Tech Acquisition Corporation (EM) shares are in issue?

Genesis Growth Tech Acquisition Corporation (EM) has 6,338,637 shares in issue

What is the market cap of Genesis Growth Tech Acquisition Corporation (EM)?

The market capitalisation of Genesis Growth Tech Acquisition Corporation (EM) is USD 34.1M

What is the 1 year trading range for Genesis Growth Tech Acquisition Corporation (EM) share price?

Genesis Growth Tech Acquisition Corporation (EM) has traded in the range of US$ 5.38 to US$ 5.38 during the past year

What is the PE ratio of Genesis Growth Tech Acquisition Corporation (EM)?

The price to earnings ratio of Genesis Growth Tech Acquisition Corporation (EM) is -28.87

What is the registered address of Genesis Growth Tech Acquisition Corporation (EM)?

The registered address for Genesis Growth Tech Acquisition Corporation (EM) is Bahnhofstrasse 3, Hergiswil, Nidwalden, 6052

What is the Genesis Growth Tech Acquisition Corporation (EM) website address?

The website address for Genesis Growth Tech Acquisition Corporation (EM) is www.genesisgrowthtechspac.com

rosemountbomber

rosemountbomber 16分前

It is the consensus view because company management and the FDA have not given us reason to believe otherwise. As far as the AI take in your following post how ridiculous that the 2nd CRL to cite the same deficiencies as the first. They never did a second inspection to discover those deficiencies.

Genz2

https://www.macrumors.com/2026/07/09/apple-prismml-larger-on-device-ai-models/

Has Tesla/SpaceXAI thought about working with a company like PrismML so that they could efficiently run Grok/MacroHard and use less memory in Dell, HP or Lenovo computers? The PrismML could reduce the memor

Slojab

Slojab 18分前

Pretty ridiculous, huh? You should be able to have a negative market cap. 🤣

smoki

F’ing A ….blasting off get your free ride NOW!!! $$$$$$$$$ …Blozf goos Blo ^^^^^^^^^^^^:))))))

BahamaPete

BahamaPete 27分前

Thanks OCKHAM's RAZOR, I added your links to my DD post. Go $TKOI

Helter Skelter

Helter Skelter 37分前

😆 "accurately captures one of the most critical underappreciated alliances..."

https://investorshub.advfn.com/uimage/uploads/2026/7/10/opnhmBB_Can_u_say_MONOPOLY_071026.png

🤑 $BB Where Nvidia Goes We Go $NVDA 🤑

Twiggs333

Twiggs333 43分前

CMPS Compass Pathways: A Structural Mispricing in Plain Sight?

Extremely good explanation of the value of this company by a Stanford Professor.

https://x.com/kevin__mak/status/2075541715272790373

Popeye

Popeye 44分前

Yeah, agreed. That was a shot of the dark guess of the discount for the Reg A and .08 would certainly move the numbers in the favor of the shareholder.
Unknowns are 1. What will the discount be and 2. How much will Korenko raise? (Doesn’t have to raise the entire $9 million now - maybe raise

Twiggs333

Twiggs333 45分前

Compass Pathways: A Structural Mispricing in Plain Sight?

https://x.com/kevin__mak/status/2075541715272790373

CA Market News

CA Market News 49分前

Lion One Announces Closing of Second Tranche of Non-Brokered Private Placement of Convertible Debenture Units and Units for Aggregate Gross Proceeds of $17.5 MillionJuly 10, 2026 11:14 PM
Newsfile

Genz2

Sorry, misspelled Greg’s last name in the previous post!!! It should be Kazmierczak!!

Gus1212

Gus1212 58分前

If this rejection theory is correct, I believe it was just a tactic to stall our approval process.
Sounds too simple, doesn't it!

Maybe paid for by you know who, big pharma.

They all know that DCVAX works; they are not dummies.
Why did they stall? Cou

Whalatane

Whalatane 1時間前

A Fable 5 analysis
Synthesized FDA timeline risks, TDAPA reimbursement implications, and dilution concernsSynthesized FDA timeline risks, TDAPA reimbursement implications, and dilution concernsGood context to layer in.
Here's the deeper risk breakdown on those three fronts.

LTR

I think a suitable punishment for these guys would be to lock them up in ILT's vault and throw away the key.

Real McCoy

Real McCoy 1時間前

Well yeah this one has the most lies.

3rd attempt: you ok with lies, yes or no?

pos_stock_hoarder

pos_stock_hoarder 1時間前

New York Dolls - Looking for a Kiss

https://youtu.be/GvmvMFXWzc8

Genz2

Genz2 1時間前

https://techcrunch.com/2026/07/10/us-cyber-agency-cisa-had-to-build-its-incident-playbook-during-the-incident-agency-reveals/

According to Krebs, the researcher tried to alert the contractor but didn’t hear back. Only after Krebs contacted CISA did the agency take the repository offli

boston127

boston127 1時間前

Hey,

Thanks for the links you sent me. My PC blocked all of the URLs due to malware protection. I'm still in GNIS and the other one. I was up but they have dive bombed quite rapidly. Now, in the RED. Both companies are interesting.

LTR

I have an idea AF may turn up in discovery when the dots are lined up and connected. AF may look to be a witness in order to avoid being a defendent.

conix

conix 1時間前

Non-promotional information until there is a press release is a wise move.

CatfishHunter

CatfishHunter 1時間前

We should have news of next step well before years end. Vivos is already approved by FDA to start the EFS. Mayo Clinic needs to review and sign off on the approved conditions for the IRB and that’s just a formality. EFS could start as early as August. And 30 day patient status report about 45 days a

Philosophical Trader

Philosophical Trader 1時間前

How is this doing? This was a great runner with a 2 year cup and handle.

nwtf

nwtf 1時間前

You really dont have a clue what you are talking about. Just stop.

Genesis Growth Tech Acqu... (EM)

Amundi Core MSCI Emergin...

Exchange Traded Fund Ivz...

Investec Bnk 24

Stellar AfricaGold

Hudson Acquisition I

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。